Investor Relations

Home > Investor Relations > IR Library > Statements of Cash Flows (consolidated)

Statements of Cash Flows (consolidated)

(million yen) 
  FY2016
(2016/4/1-2017/3/31)
FY2017
(2017/4/1-2018/3/31)
Net cash provided by operating activities 10,195 19,230
Net cash used in investing activities 22,206 20,093
Net cash provided by (used in) financing activities 92 4,670
Effect of exchange rate changes on cash and cash equivalents 689 591
Net increase in cash and cash equivalents 11,414 4,399
Cash and cash equivalents at beginning of the year 18,526 7,112
Cash and cash equivalents at end of the year 7,112 11,511

Home > Investor Relations > IR Library > Statements of Cash Flows (consolidated)
© Copyright TOWA PHARMACEUTICAL CO.,LTD. All Rights Reserved.